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Abstract
Background: A biodegradable polymeric sealant has been previously shown to reduce postoperative air leaks after
open pulmonary resection. The aim of this study was to evaluate safety and efficacy during minimally invasive
pulmonary resection.
Methods: In a multicenter prospective single-arm trial, 112 patients with a median age of 69 years (range 34–87
years) were treated with sealant for at least one intraoperative air leak after standard methods of repair (sutures,
staples or cautery) following minimally invasive pulmonary resection (Video-Assisted Thoracic Surgery (VATS) or
Robotic-Assisted). Patients were followed in hospital and 1 month after surgery for procedure-related and
device-related complications and presence of air leak.
Results: Forty patients had VATS and 72 patients had Robotic-Assisted procedures with the majority (80/112,
71%) undergoing anatomic resection (61 lobectomy, 13 segmentectomy, 6 bilobectomy). There were no
device-related adverse events. The overall morbidity rate was 41% (46/112), with major complications occurring in 16.
1% (18/112). In-hospital mortality and 30-day mortality were 1.9% (2/103). The majority of intraoperative air leaks
(107/133, 81%) were sealed after sealant application, and an additional 16% (21/133) were considered reduced.
Forty-nine percent of patients (55/112) were free of air leak throughout the entire postoperative study period.
Median chest tube duration was 2 days (range 1 – 46 days), and median length of hospitalization was 3 days
(range 1 – 20 days).
Conclusions: This study demonstrated that use of a biodegradable polymer for closure of intraoperative air leaks
as an adjunct to standard methods is safe and effective following minimally invasive pulmonary resection.
Trial registration: ClinicalTrials.gov: NCT01867658. Registered 3 May 2013.
Keywords: Lung cancer, Lung surgery, Video-assisted thoracic surgery, Robotic surgery, Intraoperative air leak,
Postoperative air leak, Pleural air leak sealant
Background
Lung cancer remains a common and deadly problem
both in the United States and worldwide [1]. When indi-
cated, primary surgical resection remains one of the most
effective treatments for lung cancer and other isolated
pulmonary conditions. Limiting postoperative morbidity
in patients undergoing pulmonary resection results in
decreased length of stay and reduced healthcare costs.[2]
One strategy to reduce postoperative complications has
been through the utilization of minimally invasive surgery
(MIS) approaches, such as Video-Assisted Thoracic Sur-
gery (VATS) and Robotic-Assisted. Multiple studies have
shown that MIS pulmonary resection has benefits over a
traditional thoracotomy approach, such as decreased
length of stay, decreased short-term postoperative pain
and fewer complications [3–6]. As a result, the utilization
of VATS and Robotic-Assisted for anatomic resection has
steadily increased [7]. In a recent review of the voluntary
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Society of Thoracic Surgery (STS) general thoracic surgery
database, the rate of utilization of thoracoscopic approaches
for lobectomy between 2000 and 2010 was approaching
nearly 50% [8].
While increasing utilization of MIS approaches reduces
overall complication rate and length of stay, one of the
most common adverse events following lung resection re-
mains prolonged air leak [9, 10]. Outside of major cardio-
pulmonary events, air leak management is one of the most
significant causes of protracted hospital stay and cost [11].
Reflective of the impact of the problem, there have been
generations of research and product development in order
to achieve meaningful reduction in air leak rates. Early
studies utilizing both routine and selective use of fibrin-
based sealants showed no difference in duration of leak,
chest tube duration, or length of stay [12–14]. The next
generations of sealants were based on the use of a syn-
thetic, water-soluble polyethylene glycol (PEG) derivative.
The first approved by the FDA utilized a PEG gel applied
to the lung surface and photopolymerized for postoperative
pneumostasis and was shown in a multicenter, prospective
randomized trial to be associated with a higher rate of pa-
tients remaining free of air leaks postoperatively [15]. The
product is no longer available in the United States.
Subsequently, a polymeric biodegradable sealant that did
not require light activation was developed by combining a
PEG-based crosslinker, functionalized with succinate groups
(PEG-(SS)2), with human serum albumin-USP just prior to
usage (Progel™ Pleural Air Leak Sealant (PALS), Bard Davol,
USA) [16]. Once mixed, Progel™ PALS polymerizes to form
a clear, flexible hydrogel matrix that adheres to the lung tis-
sue within 15 s and forms a flexible seal that can withstand
30 mmHg air pressure within 2 min of application and a
maximum burst pressure of greater than 90 mmHg in less
than 10 min. The material is completely reabsorbed within
1 month postoperatively. When Progel™ PALS was evaluated
in a multicenter, prospective randomized trial for treatment
of intraoperative air leaks following open pulmonary resec-
tion, its use was associated with a higher rate of intraopera-
tive sealing, a lower rate of postoperative air leaks, and
reduced hospital stay [17]. Based on these data, Progel™
PALS remains the only FDA-approved pneumostatic agent.
Despite data showing the efficacy of Progel™ PALS in
reducing intraoperative and postoperative air leaks fol-
lowing open pulmonary resection, there are little data
on its use during minimally invasive approaches, such as
VATS or Robotic-Assisted procedures. The purpose of
this multicenter, prospective study was to evaluate the
safety and efficacy of Progel™ PALS for sealing air leaks
incurred during MIS pulmonary resection.
Methods
This study was conducted in compliance with the United
States Code of Federal Regulations (CFR), 21 CFR Part
812, Investigational Device Exemptions, Part 56, Institu-
tional Review Boards, Part 50, Protection of Human Sub-
jects, and the ethical principles that have their origin in
the Declaration of Helsinki. Institutional review boards at
each institution approved the clinical trial prior to initi-
ation of the study. Informed consent was obtained in writ-
ing from all patients.
Patients 18 years old and older, who were scheduled
for a MIS lung resection (wedge resection, lung volume
reduction surgery, segmentectomy, lobectomy, or bilo-
bectomy), decortication, or biopsy by VATS or Robotic-
Assisted approach and who gave informed consent, were
evaluated for entry into the study. Patients had to have
at least one visible intraoperative air leak (IOAL) at the
completion of the procedure following standard closure
methods, including but not limited to suturing or stapling.
Exclusion criteria included: pregnancy, breast feeding,
known sensitivity to human albumin, history of a previous
lung resection or previous use of sealant for air leaks, renal
insufficiency with a baseline serum creatinine ≥2.5 mg/dl
or active dialysis, active or latent infection which was sys-
temic or at the intended surgical site, inability to apply
standard closure methods, or the presence of a significant
clinical disease or condition that might complicate the sur-
gery and make it difficult to evaluate the safety and effect-
iveness of the sealant.
The study was performed at 15 institutions with a mix-
ture of academic, teaching, and community hospitals.
There was a single principal investigator at each site, along
with sub-investigators, and each underwent training in
preparation and use of the sealant prior to the start of the
study. A maximum of 20 subjects were treated at each
site. Enrollment was balanced with 40 subjects under-
going VATS and 72 subjects undergoing Robotic-Assisted
procedures.
The primary objective was to assess the safety of using
the sealant after MIS pulmonary resection, and the pri-
mary endpoint was to measure the overall and major post-
operative morbidity rates. Complications were considered
as a composite rate of device- and procedure-related
events and were graded according to the NCI Common
Terminology Criteria for Adverse Events (Version 4.03)
upon study completion. Prolonged air leak was defined as
air leak present after the 5th postoperative day. The sec-
ondary objective was to measure efficacy of the sealant for
reducing intraoperative and postoperative air leaks.
Exploratory endpoints included: the proportion of intra-
operative air leaks sealed or reduced; the proportion of pa-
tients free of air leaks immediately following surgery in
the recovery room; chest tube duration; and length of
hospitalization.
After all pulmonary resections were completed, air leaks
were identified by inflating the lung and submerging the
areas of closure within saline solution (or water) to
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observe for air bubbles. If there were no air leaks detected,
the patient was not treated. If air leaks were detected,
standard methods of closure, such as additional suturing
and stapling, were utilized, and a second leak test was per-
formed. If there were air leaks following standard closure,
the location and size of leaks were recorded, and the areas
were treated with sealant. After application of the sealant
to each of the identified air leaks, ventilation to the treated
lung was suspended or reduced for 2 min, a second leak
test was then performed, and the existence, location, and
size of leaks were again recorded. If an air leak was still
present, the investigator was permitted to reapply sealant
up to two more times or use other closure methods (e.g.,
additional sutures or staples, pleural tent, pneumoperito-
neum) to close the remaining air leak. Sealant was not ap-
plied prophylactically to areas of the lung that were not
leaking air at the time of surgery (Fig. 1).
Kits containing the sealant were stored at 2 to 8 °C
prior to usage. Each kit included two glass cartridges
(one with human serum albumin-USP and the other
with powdered crosslinker PEG), a syringe, and a vial of
sterile water to rehydrate the powdered crosslinker just
prior to usage. A double-barreled applicator was used
for housing the two cartridges with a special tip to facili-
tate mixing of the components and to spray the mixture
onto the lung. Each kit was supplied sterile and contained
4 mL of sealant.
Chest tubes were placed on 20 to 25 cm H2O suction
for 24 h, after which they were placed to water seal if no
air leak was detected. If an air leak remained after 24 h,
the switch to water seal was done at the discretion of each
investigator. The use of digital, regulated intrapleural pres-
sure drains were allowed. Chest tubes were removed when
the following occurred: there was no air leak following the
switch to water seal; the lung had expanded sufficiently, or
in the investigator’s opinion, there was no significant in-
crease in the size of a pneumothorax that would prevent
removal; and volume of drainage <5 cc/kg/24 h or <2.5 cc/
kg/12 h. The duration of Post Operative Air Leak (POAL)
was measured from the day of surgery until the chest tube
was removed. Air leaks were assessed by qualified hospital
staff, including investigators, nurses, study coordinators,
physician assistants, and residents. If there were multiple
readings at a designated air leak assessment time and a dis-
crepancy was observed between readings, the investigator’s
assessment was utilized. Chest roentgenograms (CXR)
were obtained preoperatively, within 6 h of surgery, within
24 h prior to and after chest tube removal, and at 1-month
follow-up. Some patients who had a prolonged air leak
were discharged from the hospital with the chest tube
connected to a Heimlich or Pneumostat™ valve. When
this occurred, the patient was asked to return weekly
for air leak assessment until the chest tube was re-
moved. Chest tube duration was measured from the
day of surgery to the day the last chest tube was re-
moved. Patients were followed up at 1 month where
they had a physical examination, CXR, and blood tests
(blood urea nitrogen, creatinine, glomerular filtration
rate) and were questioned about complications since
discharge from the hospital.
Fig. 1 Intraoperative Protocol Schematic
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A Clinical Events Committee (CEC) comprised of in-
dependent lung surgeons specializing in minimally inva-
sive surgery, adjudicated all adverse events in this study
for seriousness and for device and procedure relation-
ship. All protocol-required CXRs were evaluated by an
independent core laboratory for changes in lung expan-
sion, presence or absence of pneumothorax, as well as
size of pneumothorax.
Statistical analysis was performed using SAS software
version 9.3 in accordance with the trial statistical analysis
plan. All analyses were based on the modified intent-to-
treat population that included those subjects who under-
went successful VATS or Robotic-Assisted procedure and
were treated with sealant. The key secondary endpoint of
the study that measures the effectiveness of the treatment
was the proportion of subjects without postoperative air
leaks following lung surgery up to 1-month follow-up.
The study was designed to treat approximately 105 sub-
jects in order to obtain 100 evaluable subjects followed
through the 1-month follow-up visit after allowing for 5%
loss to follow-up.
Results
There were 207 patients screened for participation, and
192 who met baseline eligibility were enrolled. There
were 112 patients treated on protocol, and 80 who were
not treated. The reasons for not treating these patients
are listed in Fig. 2. The most common reason (n = 69)
was either absence of intraoperative air leak following
standard methods of closure or inability to utilize stand-
ard closure techniques. All 112 patients were tracked
until discharge; however, 9 patients did not complete the
trial through the 30-day postoperative time-point follow-
ing treatment (Fig. 2).
There were 66 women and 46 men evaluated. Demo-
graphics and clinical characteristics are listed in Table 1.
In general the group had good preoperative lung func-
tion, and the most common indication for surgery was a
primary lung tumor. The surgical procedures performed
are listed in Table 2. The most common operation per-
formed was lobectomy (61/112), and overall anatomic
lung resection was performed in 71% of patients (80/112).
Eleven patients underwent more than one pulmonary
procedure, but only the most extensive resection was
counted. More patients underwent Robotic-Assisted
procedures (72 versus 40), and a slightly higher propor-
tion of Robotic-Assisted procedure patients underwent
anatomic pulmonary resection 54/72 (75%) compared
with VATS patients 26/40 (65%). There were 133 identi-
fied air leaks, among 112 subjects. In the majority of
cases only one application of sealant was required to
treat identified intraoperative air leaks 108/133 (81.2%).
Fig. 2 Disposition of patients and primary reasons patients were screened but not treated
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Morbidity
There were no observed device-related adverse events.
The overall complication rate for the entire treated
group was 41% (46/112). Major complications, as defined
as NCI CTCAE (v4.03) [18] grade 3 or higher adverse
events, occurred in 18 patients (16.1%) (Table 3). Pro-
longed air leak was the most common single major adverse
event, occurring in 10 patients (8.9%). Of the 10 patients
with prolonged air leak, six were considered major because
they required additional intervention, such as insertion of
an additional chest tube or chemical pleurodesis. Two such
patients underwent reoperation — one had bleb resection,
and one had creation of a pleural tent. An additional 5
patients underwent reoperation for indications includ-
ing postoperative hemorrhage, pulmonary torsion, and
repair of bronchopleural fistula, for a total reoperation
rate of 6.3% (7/112).
In-hospital mortality and 30-day mortality were each
1.9% (2/103). One patient underwent Robotic-Assisted
lobectomy and developed right upper lobe torsion necessi-
tating reoperation. Postoperatively the patient suffered
sudden cardiac arrest and expired on postoperative day
13. The second patient underwent Robotic-Assisted lobec-
tomy and suffered aspiration pneumonitis on postoper-
ative day 2. This progressed to acute respiratory distress
and multi-system organ failure. The patient had with-
drawal of care and died on postoperative day 11.
There were a total of 133 intraoperative air leaks iden-
tified in 112 patients (Table 4). The most common site
of leak was from the area of the staple line (98/133,
74%). The median number of applications of sealant was
1 (range 1–3), and 80% (107/133) of leaks were sealed at
Table 1 Patient Characteristics









Previous myocardial infarction 7
Cardiovascular disease 37
History of stroke 4
History of transient ischemic attack 4
Congestive heart failure 5
COPD 34
Alcohol abuse (Past and Current) 11
Diagnosis/Indications for surgery
Primary tumor 96 86
Metastatic tumor 5 4






Pulmonary function tests (n = 101)
FEV1 % predicted (mean ± SD) 81.2 ± 24.3
FVC % predicted (mean ± SD) 86.0 ± 25.5
DLCO % predicted (mean ± SD) 70.9 ± 25.0
COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume in
1 s, FVC forced vital capacity, DLCO diffusing capacity of carbon monoxide
aOther diagnosis include: COPD, chronic bronchitis, aspergilloma, bleb
Table 2 Perioperative Details
n = 112 VATS (n = 40) Robotic-Assisted
(n = 72)
Operative proceduresa
Wedge resection 29 14 15
Segmentectomy 13 4 9
Lobectomy 61 21 40
Bilobectomy 6 1 5
Decortication 2 0 2
Biopsy 1 0 1
Median OR time,
minutes (range)
214.5 (79 – 433)
VATS video-assisted thoracic surgery, OR operating room
aEleven subjects had more than one procedure; only the most extensive
procedure was counted
Table 3 Major Complicationsa
Prolonged air leak 6
Postoperative hemorrhage 3
Pleural effusion 2









Positive resection margin 1
Multi-organ failure 1
Total 23
Terminology Criteria for Adverse Events (v4.03)
aMajor complications defined as Grade 3 or higher as per National Cancer
Institute Common
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the time of operation, while another 21 (16%) were re-
duced. Postoperatively, 61% of patients had no leak in
the post-anesthesia care unit, and 49% of patients dem-
onstrated no air leak up through the 1 month postopera-
tive visit (Table 5). The median chest tube duration was
2 days (range 1 – 46), and the median length of stay for
the entire cohort was 3 days (range 1 – 20). Eight pa-
tients were discharged with a chest tube in place and
had removal in the outpatient setting.
Discussion
This is the first study, prospective or otherwise, evaluat-
ing the feasibility of utilizing lung sealant following min-
imally invasive lung resection. It demonstrated that the
use of Progel™ PALS was safe, with no device-related
morbidity and with overall major procedural morbidity
rates that were consistent with similar large series of
VATS and Robotic-Assisted lung resections [3, 4, 6, 7].
Boffa and co-authors recently reported results of a
retrospective study of VATS versus open anatomic
lung resections from 11,531 patients in the voluntary
Society of Thoracic Surgeons database [19]. The overall
complication rate for VATS was 30%, with an operative
mortality rate of 1.3%. By comparison, in our study the
overall morbidity was 41% with an operative mortality rate
of 1.9%. Taking into account the prospective nature of the
current study, the results are acceptable. In addition, the
observed chest tube duration and length of stay were
substantially shorter than the comparable data from the
previous randomized trial (Table 5).
To date, this is the only experience in a cohort under-
going exclusively minimally invasive thoracic surgery.
The previous prospective, randomized trial that demon-
strated efficacy of this solitary FDA-approved product to
seal intraoperative air leaks and reduce length of stay
was almost exclusively in patients undergoing thoracot-
omy [17]. Two other prospective, randomized studies of
an alternative polyethylene glycol matrix (currently not
approved for use in the United States) were conducted
as adjuncts to predominantly open approaches [20, 21].
In the more recent report, while the authors stated that
some proportion of procedures were performed by
VATS, they did not report the distribution of surgical
approach [21].
The secondary endpoints observed regarding the effi-
cacy of the sealant were also promising and consistent
with the prior efficacy study (Tables 4 and 5). Intraoper-
ative air leaks were sealed (21/133, 15.8%) or reduced
(107/133, 80.4%) in 96.2% of cases, and 49% of the pa-
tients had no evidence of air leak through 1-month of
postoperative follow-up. This compares favorably with
the results reported by Allen and colleagues, who ob-
served that 35% of patients experienced freedom from
air leak throughout the entire 1-month follow-up, versus
only 14% of the control group. Similarly, Klijian per-
formed a retrospective review of a single institution ex-
perience comparing patients undergoing lung resection
who received intraoperative pleural sealant with those
who did not [22]. In individuals with intraoperative air
leak, the use of sealant was associated with a significant
decrease in the incidence of postoperative air leak (11%
in the sealant group versus 58.8% in the control group,
p <0.0001) as well as shorter chest tube duration and
hospital stay.
The strengths of the current study include the pro-
spective multicenter design, rigorous prospective docu-
mentation of potential product- and procedural-related
complications, and the standardization of intraoperative
air leak assessment and subsequent treatment. In par-
ticular, the requirement that patients must have a dem-
onstrable intraoperative air leak to be treated, while not
necessary to determine the safety of the product, elimi-
nated unnecessary treatment and allowed for evaluation
of secondary efficacy outcomes.
There are some limitations of this report. The treat-
ment population was somewhat heterogeneous, with a
Table 4 Intraoperative Air Leaks (IOAL)
Variable Number of Air Leaks (n = 133) Percent (%)
Source of air leak
Suture line 9 6.7
Staple line 98 73.8
Lung surface 12 9.0
Torn lung 5 3.8
Fissure 9 6.7
Final assessment of IOAL
Not sealed 5 3.8
Reduced 21 15.8
Sealed 107 80.4
Table 5 Comparative Efficacy of Progel™ PALS in MIS and Open
Studies







Air leaks sealed in the OR 80% 77% 16%
Air leaks sealed immediately
following surgery
60.7% 54% 33%
Air leaks sealed through
1 month post-operative
49.1% 35% 14%
Median duration of post-op
air leakage
1.0 day 2 days 2 days
Median chest tube duration 2.0 days 5 days 5 days
Median length of stay 3.0 days 6 days 7 days
MIS minimally invasive surgery, PALS pleural air leak sealant, OR operating room
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mixture of patients undergoing non-anatomic and ana-
tomic resection, as well as different minimally invasive
approaches (VATS and Robotic-Assisted). Moreover, with-
out a control group undergoing only standard methods to
prevent air leak, conclusions about the efficacy of the seal-
ant by comparison to historical data is limited. A follow-
up study utilizing a prospective, randomized case-control
methodology to more rigorously evaluate efficacy would
be ideal. Included in the study should be a planned
cost-effectiveness analysis as well, to determine whether
any potential clinical benefit also has an acceptable cost
profile.
Conclusions
The use of PEG cross-linked with human serum albumin
as a pneumostatic agent for patients with intraoperative
air leak following minimally invasive pulmonary resection
is safe and efficacious. In addition, its use does not appear
to be associated with increased procedural morbidity or
mortality. Based upon the results of the study, the prod-
uct’s use was observed to reduce intraoperative air leak
and should be considered for use on pleural air leaks iden-
tified during lung resection in open or minimally invasive
procedures.
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